|
| [January 16, 2013] |
 |
Research and Markets: Competitor Analysis: Herpes Virus Vaccines and Therapeutics
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/7jzws6/competitor)
has announced the addition of the "Competitor
Analysis: Herpes Virus Vaccines and Therapeutics" report to
their offering.
The present Competitive Intelligence Report about Herpes Virus Vaccines
& Therapeutics provides a competitor evaluation in the field of
prophylactic vaccines and therapeutic antibodies and small molecules
against infection caused by herpes simplex virus (HSV) type 1 and/or
type 2 and varicella zoster virus (VZV) or human herpes virus type 3
(HHV-3) as of December 2012. Purchase of the downloadable pdf report
includes a 6-month online access to the data of the report and any
updates since the publication date. Credentials to access the database
will be sent by e-mail and allow online work with the project data to
rint or export an individual report.
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human
herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus
family that infect humans. HSV-1 and HSV-2 cause the viral disease
herpes simplex which can be categorized into one of several distinct
disorders based on the site of infection: oral herpes with the visible
symptoms of cold sores or fever blisters, genital herpes and other forms
including ocular herpes (keratitis).
Varicella zoster virus (VZV) is another of eight herpes viruses known to
infect humans. It commonly causes chicken-pox in children and both
shingles and postherpetic neuralgia in adults and rarely in children.
Varicella zoster virus is known by many names, including: chickenpox
virus, varicella virus, zoster virus, and human herpes virus type 3
(HHV-3).
The report includes a compilation of marketed and currently active
projects in development of vaccines, antibodies and small molecules
targeting herpes simplex virus type 1 or type 2 (HSV-1 or HSV-2) and
varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) for
prophylaxis and treatment of oral herpes, genital herpes, chickenpox
(varicella) and herpes zoster, respectively. In addition, the report
lists company-specific R&D pipelines of Herpes Virus Vaccines &
Therapeutics.
Competitor projects are listed in a tabular format providing information
on:
- Drug Codes,
- Target (News - Alert) / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage
- additional comments with a hyperlink leading to the source of
information.
For more information visit http://www.researchandmarkets.com/research/7jzws6/competitor

[ InfoTech Spotlight's Homepage ]
|